Kynamro

Q: What is Kynamro used for?

<p>Kynamro can be used in addition to other <a href="https://www.withpower.com/clinical-trials/cholesterol">cholesterol</a>-lowering medications and a healthy <a href="https://www.withpower.com/clinical-trials/diet">diet</a> to help reduce levels of low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).</p>

Homozygous Familial Hypercholesterolemia

Treatment

1 FDA approval

3 Active Studies for Kynamro

Treatment for

Homozygous Familial Hypercholesterolemia

What is Kynamro

MipomersenThe Generic name of this drug

Treatment SummaryMipomersen sodium, also known as Kynamro, is a drug used to treat homozygous familial hypercholesterolemia, a genetic disorder that causes high levels of cholesterol and other fats in the blood. Mipomersen works by blocking the formation of Apo B-100 and reducing levels of LDL cholesterol and total cholesterol. This drug carries a black box warning due to its potential to cause liver damage, so it is only available to patients under a special safety program called the Kynamro Risk Evaluation and Mitigation Strategy program.

Kynamrois the brand name

image of different drug pills on a surface

Kynamro Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kynamro

Mipomersen

2013

Approved as Treatment by the FDA

Mipomersen, otherwise called Kynamro, is approved by the FDA for 1 uses which include Homozygous Familial Hypercholesterolemia .

Homozygous Familial Hypercholesterolemia

Helps manage Homozygous Familial Hypercholesterolaemia (HoFH)

Effectiveness

How Kynamro Affects PatientsMipomersen sodium helps to lower the amount of cholesterol and other fats in the blood, including apolipoprotein B, low density lipoprotein, and non-high density lipoprotein cholesterol.

How Kynamro works in the bodyMipomersen attaches to the instructions that tell the body to make apoB-100. This prevents the body from using those instructions, and so the protein is not made.

When to interrupt dosage

The amount of Kynamro depends on the diagnosed affliction. The quantity of dosage is contingent upon the technique of delivery delineated in the table below.

Condition

Dosage

Administration

Homozygous Familial Hypercholesterolemia

, 200.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution

Warnings

Kynamro has four contraindications and should not be utilized when encountering the conditions presented in the subsequent table.Kynamro Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Moderate Hepatic Impairment

Do Not Combine

Transaminases

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

There are 2 known major drug interactions with Kynamro.

Common Kynamro Drug Interactions

Drug Name

Risk Level

Description

Pexidartinib

Major

Mipomersen may increase the hepatotoxic activities of Pexidartinib.

Methotrexate

Moderate

Mipomersen may increase the hepatotoxic activities of Methotrexate.

Kynamro Toxicity & Overdose RiskMipomersem has a black box warning of potential liver damage. Other, less serious side effects include nausea, headache, fatigue, and pain or discomfort at the injection site. Some people may also experience similar symptoms to the flu.

image of a doctor in a lab doing drug, clinical research

Kynamro Novel Uses: Which Conditions Have a Clinical Trial Featuring Kynamro?

Five active studies are currently assessing the potential of Kynamro in treating Homozygous Familial Hypercholesterolemia.

Condition

Clinical Trials

Trial Phases

Homozygous Familial Hypercholesterolemia

3 Actively Recruiting

Phase 3, Phase 2

Kynamro Reviews: What are patients saying about Kynamro?

3Patient Review

3/29/2013

Kynamro for Homozygous Inherited High Blood Cholesterol

I've been using KYNAMRO injections on patients with familial hyperlipidemia and have seen good results in terms of lipid profiles, specifically LDL and triglycerides.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kynamro

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does mipomersen work?

"The drug mipomersen works by binding to a specific RNA sequence, which in turn prevents the production of a protein called apoB."

Answered by AI

When was Kynamro discontinued?

"As of August 2019, Kynamro (mipomersen) is no longer available in the United States. It is unclear why the FDA withdrew its approval for this medication."

Answered by AI

What is Kynamro used for?

"Kynamro can be used in addition to other cholesterol-lowering medications and a healthy diet to help reduce levels of low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."

Answered by AI

What is the mechanism of action of lomitapide?

"As a result, hepatic secretion of triglycerides, apolipoprotein B-100 and cholesterol are decreased.

The microsomal triglyceride transfer protein (MTP or MTTP) is necessary for very low-density lipoprotein (VLDL) assembly and secretion in the liver. Lomitapide decreases the MTP, which then decreases the hepatic secretion of triglycerides, apolipoprotein B-100 and cholesterol."

Answered by AI